Life sciences investment group and part of global investment firm Carlyle, Abingworth announced last week it had exceeded its $300 million target by $56 million.
Integrated drug formulation and clinical trials company, BDD Pharma, will be expanding its phase appropriate development, manufacturing, and clinical testing services after a £2 million ($1.3 million) investment.
Global Healthcare Opportunities (GHO) Capital Partners LLP along with Partners Group has announced today (May 25) that it has invested an undisclosed amount in GHO portfolio company, Sterling Pharma Solutions.
The imaging company’s newly launched division, created to produce drug ingredients, received the loan from the US International Development Finance Corp.
Thousand Oaks Biopharmaceuticals raised $45m in Series A financing, enabling the company to expand its CDMO and CMC services as well as its capabilities in global biologics development.
Encouraged by a North Carolina state grant, Fresenius Kabi will expand its prefilled syringes business acquired from Becton, Dickinson and Company in 2016.
Helomics Corporation and Pittsburgh Life Sciences Greenhouse (PLSG) have collaborated to form a biotechnology incubator with a precision and diagnostics medicine focus.
The global central laboratory and support services provider has secured a $24.5m Series A investment and is on track to double in size, again, over the next five years, says CEO.
Atlas Genetics has said it will expand manufacturing capacity for cartridge-based STI tests at a UK facility owned by drug delivery technology firm Bespak Europe ltd.
Fresenius Kabi has said it will increase manufacturing capacity and create jobs at a site in Illinois in a move that will earn the German firm US tax breaks.
For the third year in a row, about 30% of Deloitte poll respondents say their companies experienced supply chain fraud, waste, or abuse in the previous year.
The UK’s Biomedical Catalyst funding scheme encourages investors to back innovative biopharma research and should be continued according to the BioIndustry Association (BIA).
Investor backing puts transparency on the pharma agenda says SenseAboutScience, even though none of the funds pledging support for Alltrials have committed to pull investment from drug firms that disagree.
China-based contract research and manufacturing company WuXi PharmaTech has received a proposal to be taken private by a consortium led by its CEO and Ally Bridge Group Capital Partners.
With sky-high valuations and soaring M&A prices, the question of whether there’s a biotech bubble continues to crop up, though now some analysts are saying this so-called bubble and its inevitable pop may be a cause for concern for CROs (contract...
China-based CRO WuXi PharmaTech has entered into a syndicated loan facility to borrow up to $165m from a consortium of banks in Asia to seek out new acquisitions.
Biopharma companies are not likely to outsource a larger chunk of their manufacturing than they have in the past 10 years, according to a new report from PharmSource.
Clinverse, a provider of automated financial management tech solutions for clinical trials, has closed a $9.1m (€6.9m) round of funding led by New Jersey-based Edison Partners.
Biopharma firms continued to attract US venture capital investment in Q1 according to new analysis by PricewaterhouseCoopers (PwC), which says the number of firms that received backing is encouraging.
The UK Government has set out to make Britain a more attractive place from which to source drugs and ingredients by awarding a series of taxpayer funded grants to supply chain focused innovation projects.
Indian contract manufacturer Surya Pharmaceutical has received an EDQM Certificate of Suitability (CEP) for an antibiotic API and approval for its Banur plant from Teva.
PPD posted an improved set of financials for Q2 days after announcing a review of its long-term plan and capital structure following speculation it was looking for a buyer.
Cytovance Biologics, the US-based biopharmaceutical contract manufacturer (CMO), has secured a growth equity investment from Connecticut, US-based private investors, Great Point Partners.
West Pharmaceutical Services will invest $29m to expand its syringe plungers and intravenous (IV) system components facility in Kinston, North Carolina, in the US.
Ugandan drugmaker Quality Chemicals Industries (QCI) will invest $80m in manufacturing operations to boost capacity for the production of generic AIDS and malaria drugs.
US CRO and central laboratory services provider Pacific Biometrics (PBI) has entered into a $4m (€2.7m) loan agreement that it says will help further the development of its contract biomarkers business.
Creative thinking is required by biotechs if they are to stay afloat despite the lack of funding, according to a report by Ernst & Young, and this could reshape the landscape of the industry.
Affymetrix’s service division posted a 37 per cent increase in revenues in Q1 but overall the company slumped, going from $46m (€35m) profit in 2008 to a $25m loss this year.
Biotech bodies from around the globe have been calling on their respective governments to provide stimulus packages to compensate for the current difficulties in obtaining credit.
Canadian contract manufacturer PharmEng International has managed to trim down its costs once again, but is still feeling the pain associated with the opening of its new facility in Sydney, Nova Scotia, and posted a loss of over C$8m (€5m).
Contract manufacturer Nectar Lifesciences is to invest around RS 6bn ($141m) in a new bulk drug and pharmaceutical intermediate manufacturing facility in India's northern Punjab state.
Up to 95 clinical trials testing experimental anticancer drugs may
have to be delayed or closed altogether because of federal funding
cuts, according to the Cancer Cooperative Groups.
Hill Top Research, one of the leading clinical research services
companies in the US, has positioned itself for growth after last
week's acquisition by Utah's DW Healthcare Partners, a private
equity firm focused on the...
